Similarly, studies in cancer patients showed an expansion of CD14−CD15+CD11b+ G-MDSC population with the ability to inhibit T cell function via ROS- and arginase-1-dependent mechanisms [6], [9], [10], [47]. This evidence concerns the gene ITGAM and cancer.